PANITUMUMAB PLUS FOLFOX4 OR PANITUMUMAB PLUS FOLFIRI IN SUBJECTS WITH WILD-TYPE KRAS (EXON 2) COLORECTAL CANCER AND MULTIPLE OR UNRESECTABLE LIVER-LIMITED METASTASES: DATA FROM THE RANDOMIZED, PHASE II PLANET STUDY

被引：2

作者：

Abad, A. ^{[1
]}

Massuti, B. ^{[2
]}

Gravalos, C. ^{[3
]}

Escudero, P. ^{[4
]}

Guillen-Ponce, C. ^{[5
]}

Layos, L. ^{[6
]}

Gomez, M. A. ^{[7
]}

Safont, M. J. ^{[8
]}

Gallego, J. ^{[9
]}

Sastre, J. ^{[10
]}

Pericay, C. ^{[11
]}

Duenas, R. ^{[12
]}

Lopez-Lopez, C. ^{[13
]}

Losa, F. ^{[14
]}

Valladares, M. ^{[15
]}

Gonzalez-Flores, E. ^{[16
]}

Yuste, A. ^{[17
]}

Robles, L. ^{[18
]}

Saenz, A. ^{[4
]}

Cano, T. ^{[19
]}

Carrato, A. ^{[5
]}

Aranda, E. ^{[7
]}

机构：

[1] Hosp Sanitas Milenium Iradier, Barcelona, Spain

[2] H Gen Univ Alicante, Alicante, Spain

[3] H 12 Octubre, Madrid, Spain

[4] Univ Lozano Blesa, Hosp Clin, Zaragoza, Spain

[5] Hosp Ramon & Cajal, E-28034 Madrid, Spain

[6] Hosp Badalona Germans Trias & Pujol, ICO, Badalona, Spain

[7] H Reina Sofia, Cordoba, Spain

[8] Hosp Gen Valencia, Valencia, Spain

[9] Hosp Elche, Elche, Spain

[10] Serv Oncol Med HC, Madrid, Spain

[11] Inst Univ UAB, Corp Sanitaria Parc Tauli, Sabadell, Spain

[12] Complejo Hosp Jaen, Jaen, Spain

[13] Hosp Univ Marques Valdecilla, Santander, Spain

[14] Hosp Llobregat, H Gen Hosp, Barcelona, Spain

[15] Univ A Coruna, Complejo Hosp, La Coruna, Spain

[16] Hosp Univ Virgen Nieves, Granada, Spain

[17] Hosp Gen Univ Alicante, Alicante, Spain

[18] Hosp 12 Octubre, E-28041 Madrid, Spain

[19] Hosp Univ Reina Sofia, Cordoba, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷

关键词：

D O I：

10.1093/annonc/mdu164.6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD - 0006

引用

页码：8 / 8

页数：1

共 50 条

[1] Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.
Abad, Albert
Massuti, Bartomeu
Gravalos, Cristina
Escudero, Pilar
Guillen, Carmen
Luis Manzano, Jose
Auxiliadora Gomez, M.
Jose Safont, Maria
Gallego Plazas, Javier
Sastre, Javier
Pericay, Carles
Duenas, Rosario
Lopez-Lopez, Carlos
Losa, Ferran
Valladares Ayerbes, Manuel
Gonzalez, Encarnacion
Yuste, Ana
Carrato, Alfredo
Aranda, Enrique
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Carrato, Alfredo
Abad, Albert
Massuti, Bartomeu
Gravalos, Cristina
Escudero, Pilar
Longo-Munoz, Federico
Manzano, Jose-Luis
Gomez, Auxiliadora
Safont, Maria Jose
Gallego, Javier
Garcia-Paredes, Beatriz
Pericay, Carles
Duenas, Rosario
Rivera, Fernando
Losa, Ferran
Valladares-Ayerbes, Manuel
Gonalez, Encarnacion
Aranda, Enrique
EUROPEAN JOURNAL OF CANCER, 2017, 81 : 191 - 202
[3] A RANDOMIZED, CONTROLLED TRIAL OF CETUXIMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH KRAS WILD-TYPE UNRESECTABLE COLORECTAL LIVER-LIMITED METASTASES
Xu, J.
Ye, L.
Ren, L.
Wei, Y.
ANNALS OF ONCOLOGY, 2012, 23 : 190 - 190
[4] Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases
Ye, Le-Chi
Liu, Tian-Shu
Ren, Li
Wei, Ye
Zhu, De-Xiang
Zai, Sheng-Yong
Ye, Qing-Hai
Yu, Yiyi
Xu, Bo
Qin, Xin-Yu
Xu, Jianmin
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) : 1931 - 1938
[5] A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Bendell, Johanna C.
Zakari, Ahmed
Peyton, James D.
Boccia, Ralph
Moskowitz, Mark
Gian, Victor
Lipman, Andrew
Waterhouse, David
LoCicero, Richard
Earwood, Chris
Lane, Cassie M.
Meluch, Anthony
ONCOLOGIST, 2016, 21 (03): : 279 - 280
[6] Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G
Shitara, Kohei
Yonesaka, Kimio
Denda, Tadamichi
Yamazaki, Kentaro
Moriwaki, Toshikazu
Tsuda, Masahiro
Takano, Toshimi
Okuda, Hiroyuki
Nishina, Tomohiro
Sakai, Kazuko
Nishio, Kazuto
Tokunaga, Shoji
Yamanaka, Takeharu
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
CANCER SCIENCE, 2016, 107 (12) : 1843 - 1850
[7] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
Strickler, John H.
Rushing, Christel N.
Uronis, Hope Elizabeth
Morse, Michael
Blobe, Gerard C.
Zafar, Yousuf
Hsu, Shiaowen David
Arrowood, Christy
Ley, Sherri Ha
Dropkin, Evan
Niedzwiecki, Donna
Hurwitz, Herbert
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Trial in progress: A phase II study of second-line FOLFIRI plus panitumumab after first-line FOLFOX plus panitumumab for RAS wild-type colorectal cancer with evaluation of circulating tumor DNA.
Maeda, Hiromichi
Nagata, Naoki
Nagasaka, Takeshi
Oba, Koji
Mishima, Hideyuki
Kato, Takeshi
Yoshida, Kazuhiro
Muro, Kei
Sakamoto, Junichi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[9] The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
Francesca Battaglin
Marta Schirripa
Federica Buggin
Filippo Pietrantonio
Federica Morano
Giorgia Boscolo
Giuseppe Tonini
Eufemia Stefania Lutrino
Jessica Lucchetti
Lisa Salvatore
Alessandro Passardi
Chiara Cremolini
Ermenegildo Arnoldi
Mario Scartozzi
Nicoletta Pella
Luca Boni
Francesca Bergamo
Vittorina Zagonel
Fotios Loupakis
Sara Lonardi
BMC Cancer, 18
[10] The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
Battaglin, Francesca
Schirripa, Marta
Buggin, Federica
Pietrantonio, Filippo
Morano, Federica
Boscolo, Giorgia
Tonini, Giuseppe
Lutrino, Eufemia Stefania
Lucchetti, Jessica
Salvatore, Lisa
Passardi, Alessandro
Cremolini, Chiara
Arnoldi, Ermenegildo
Scartozzi, Mario
Pella, Nicoletta
Boni, Luca
Bergamo, Francesca
Zagonel, Vittorina
Loupakis, Fotios
Lonardi, Sara
BMC CANCER, 2018, 18

← 1 2 3 4 5 →